文献速递淋巴瘤

R-CHOP方案在晚期结节性淋巴细胞为主型霍奇金淋巴瘤中显示出令人鼓舞的活性

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
PubMed 文献 · Blood · 2017-05-18

该回顾性研究分析了1995至2015年经中心病理复核确诊的59例结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者,其中27例接受R-CHOP治疗,总缓解率100%(完全缓解89%),中位随访6.7年,5年和10年无进展生存率分别为88.5%和59.3%,R-CHOP治疗患者均未发生组织学转化,作者认为数据支持R-CHOP的潜在作用,但需更大规模前瞻性试验确定最佳化疗方案。

要点

  • 27例NLPHL患者接受R-CHOP,总缓解率100%,完全缓解率89%。
  • R-CHOP治疗患者5年和10年无进展生存率分别为88.5%和59.3%。
  • R-CHOP治疗患者均未发生组织学转化,作者认为需更大规模前瞻性试验确定最佳方案。

核心结论

  • 数据支持R-CHOP在结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者中具有潜在作用。
  • 需要更大规模的前瞻性试验来确定最佳化疗方案。

研究设计与样本

  • 回顾性分析1995年至2015年间经中心病理复核确诊的NLPHL患者,其中59例有足够治疗和随访数据可供分析。

主要发现

  • 诊断时中位年龄41岁,75%为男性,61%具有典型生长模式。
  • 27例患者接受R-CHOP治疗,总缓解率为100%(完全缓解89%)。
  • 中位随访6.7年,接受R-CHOP治疗患者的估计5年和10年无进展生存率分别为88.5%(95%CI 68.4%至96.1%)和59.3%(95%CI 25.3%至89.1%)。
  • 排除诊断时已有组织学转化的患者后,5年组织学转化累积发生率为2%(95%CI 87%至100%),接受R-CHOP治疗的患者均未发生转化。
  • 德国霍奇金研究组的高危评分对总生存(OS)有不良预后影响(P=0.036),男性性别和脾脏受累对无进展生存(PFS)有不良预后影响(P=0.006和P=0.002),但对OS无影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates of relapse and transformation. We retrospectively reviewed patients with NLPHL diagnosed between 1995 and 2015 confirmed by central pathologic review. Fifty-nine had sufficient treatment and follow-up data for analysis. We described progression-free survival (PFS), overall survival (OS), and histologic transformation according to treatment strategy and explored prognostic factors for PFS and OS. The median age at diagnosis was 41 years; 75% were male, and 61% had a typical growth pattern. Twenty-seven patients were treated with R-CHOP with an overall response rate of 100% (complete responses 89%). The median follow-up was 6.7 years, and the estimated 5- and 10-year PFS rates for patients treated with R-CHOP were 88.5% (95% confidence interval [CI], 68.4% to 96.1%) and 59.3 (95% CI, 25.3% to 89.1%), respectively. Excluding patients with histologic transformation at diagnosis, the 5-year cumulative incidence of histologic transformation was 2% (95% CI, 87% to 100%). No patient treated with R-CHOP experienced transformation. A high-risk score from the German Hodgkin Study Group was adversely prognostic for OS (P = .036), whereas male sex and splenic involvement were adversely prognostic for PFS (P = .006 and .002, respectively) but not OS. Our data support a potential role for R-CHOP in patients with NLPHL. Larger prospective trials are needed to define the optimal chemotherapy regimen.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017. PMID: 28522441. doi:10.1182/blood-2017-02-766121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。